Gambro Renal Division Gets Second Warning Letter Of The Still-New Year
This article was originally published in The Gray Sheet
Executive Summary
Two warning letters sent to Gambro in the past two months signal FDA's increasing alarm at how the firm's renal products division handles adverse event reports